Difficulty: Medium
Average Score: 66%
Practice
Diagnostic testing has resulted in a diagnosis of acute myeloid leukemia (AML) in an adult patient who is otherwise healthy. The patient and the care team have collaborated and the patient will soon begin induction therapy. The nurse should prepare the patient for which of the following?
Correct answer
D
Rationale
In the context of acute myeloid leukemia (AML), the correct answer is D) An aggressive course of chemotherapy. This is because induction therapy for AML typically involves a combination of chemotherapy agents to rapidly reduce the number of leukemia cells in the body and induce a remission. Chemotherapy is the standard first-line treatment for AML and aims to eradicate cancer cells in the bone marrow and blood.
Option A) Daily treatment with targeted therapy medications is not typically used as the primary induction therapy for AML. Targeted therapy may be used in specific cases or as a maintenance therapy after initial treatment.
Option B) Radiation therapy is not a standard first-line treatment for AML. It is more commonly used in specific situations such as central nervous system involvement or palliative care.
Option C) Hematopoietic stem cell transplantation (HSCT) is not typically part of the initial induction therapy for AML. HSCT is usually considered after achieving remission with induction therapy in order to prevent relapse or for patients with high-risk disease.
Understanding the rationale behind the choice of treatment in AML is crucial for nurses caring for patients undergoing cancer therapy. It helps them provide accurate information to patients, manage side effects effectively, and support patients through their treatment journey.
Option A) Daily treatment with targeted therapy medications is not typically used as the primary induction therapy for AML. Targeted therapy may be used in specific cases or as a maintenance therapy after initial treatment.
Option B) Radiation therapy is not a standard first-line treatment for AML. It is more commonly used in specific situations such as central nervous system involvement or palliative care.
Option C) Hematopoietic stem cell transplantation (HSCT) is not typically part of the initial induction therapy for AML. HSCT is usually considered after achieving remission with induction therapy in order to prevent relapse or for patients with high-risk disease.
Understanding the rationale behind the choice of treatment in AML is crucial for nurses caring for patients undergoing cancer therapy. It helps them provide accurate information to patients, manage side effects effectively, and support patients through their treatment journey.